Melatonin administration following serum shock differentially suppressed or induced clock gene (Bmal1 and Per2) and CCG expression in MCF10A and MCF-7 cells.

Melatonin(1mm) play a role in the paracrine interactions between malignant epithelial cells and proximal endothelial cells through a downregulatory action on VEGF expression in human breast cancer cells, as well as decreasing tumoral angiogenesis.

Direct oncostatic properties of melatonin in shift-work-cancer association.

Melatonin ( 4 times a week,20 μg/ml of drinking water) significantly reduced tumor volume in comparison with control animals.

Melatonin suppression increased breast cancer risk, in night and rotating female shift workers.

EMR increase the risk of breast cancer suppressing the production of melatonin which may modulate breast cancer through enhanced oxidative stress and Ca(2+) influx in cell lines.

Shift workers suffer from a disruption of the sleep-wake rhythm, insomnia and a lack of melatonin. These factors might trigger the development of breast cancer in female shift workers.

Melatonin or a melatonin receptor agonist may be useful biologic additions in the treatment of some forms of triple negative human breast carcinoma.

Melatonin enhance DNA repair capacity by affecting several key genes involved in DNA damage responsive pathways.

Melatonin could be an excellent adjuvant with the drugs currently used for breast cancer prevention.